IPO
Yukin Therapeutics, a French company specializing in the development of new molecules for cancer treatment, has completed a €3.3 million financing round for the development and optimization of its proprietary therapeutic molecules.
Frontage Holdings Corporation, the parent company of Frontage Laboratories, Inc., a fast-growing contract research organization, specializing in R&D product development services, with operations in both the United States and China, announced on May 30th that the Company’s Shares have initiated trading on the Main Board of The Stock Exchange of Hong Kong.
Amarantus Bioscience Holdings, Inc. released a letter to shareholders from President & CEO Gerald E. Commission
Ultragenyx Pharmaceutical Inc. announced that it will present at the following upcoming investor conferences
Founded in 2009 by brothers Chad and Harlan Robins, the company utilizes high-throughput gene sequencing with computer infrastructure that allows scientists to minutely analyze T-cell receptors.
Regenerative medicine company Orthocell Limited is pleased to announce that it has received firm commitments for a A$10.6m placement (“Placement”) from professional and sophisticated investors, including existing shareholders providing $10m net of expenses.
Retrophin, Inc. announced that Company management will present at the following upcoming investor conferences in June
Probiodrug AG, announces that its shareholders approved all resolutions proposed by the Company’s Management and Supervisory Board at the Company’s Annual General Meeting which took place on Wednesday, May 29, 2019
Upon approval by the shareholders, ASIT biotech expects to raise between €9M and €12M of convertible notes to finance its focused development
The company’s board of directors hasn’t made a final decision to proceed with the listing.
PRESS RELEASES